B 细胞在多发性硬化症中的作用：当前和未来的治疗方法。
The role of B cells in multiple sclerosis: Current and future therapies.
机构信息
Department of Biology, University of Texas at San Antonio, TX 78249, USA.
Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA; Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA.
出版信息
Cell Immunol. 2019 May;339:10-23. doi: 10.1016/j.cellimm.2018.10.006. Epub 2018 Oct 21.
Abstract
While it was long held that T cells were the primary mediators of multiple sclerosis (MS) pathogenesis, the beneficial effects observed in response to treatment with Rituximab (RTX), a monoclonal antibody (mAb) targeting CD20, shed light on a key contributor to MS that had been previously underappreciated: B cells. This has been reaffirmed by results from clinical trials testing the efficacy of subsequently developed B cell-depleting mAbs targeting CD20 as well as studies revisiting the effects of previous disease-modifying therapies (DMTs) on B cell subsets thought to modulate disease severity. In this review, we summarize current knowledge regarding the complex roles of B cells in MS pathogenesis and current and potential future B cell-directed therapies.
摘要
虽然长期以来人们一直认为 T 细胞是多发性硬化症 (MS) 发病机制的主要介质，但利妥昔单抗（RTX）治疗的疗效观察表明，B 细胞是 MS 的一个此前被低估的关键贡献者，RTX 是一种针对 CD20 的单克隆抗体。随后针对 CD20 的 B 细胞耗竭单克隆抗体的临床试验结果以及重新研究先前改变疾病疗法 (DMT) 对被认为调节疾病严重程度的 B 细胞亚群的影响的研究进一步证实了这一点。在这篇综述中，我们总结了目前关于 B 细胞在 MS 发病机制中的复杂作用以及当前和潜在的未来 B 细胞靶向治疗的知识。
相似文献
1
The role of B cells in multiple sclerosis: Current and future therapies.B 细胞在多发性硬化症中的作用：当前和未来的治疗方法。
Cell Immunol. 2019 May;339:10-23. doi: 10.1016/j.cellimm.2018.10.006. Epub 2018 Oct 21.
2
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.抗 CD20 单克隆抗体治疗复发缓解型和进展型多发性硬化症。
CNS Drugs. 2020 Mar;34(3):269-280. doi: 10.1007/s40263-020-00704-w.
3
Therapies for multiple sclerosis targeting B cells.针对B细胞的多发性硬化症治疗方法。
Croat Med J. 2019 Apr 30;60(2):87-98. doi: 10.3325/cmj.2019.60.87.
4
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.多发性硬化症治疗的里程碑：针对 CD20 的单克隆抗体——但进展仍在继续。
Neurotherapeutics. 2021 Jul;18(3):1602-1622. doi: 10.1007/s13311-021-01048-z. Epub 2021 Apr 20.
5
CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.用于治疗多发性硬化症的 CD20 单克隆抗体：最新进展。
Expert Opin Biol Ther. 2019 Aug;19(8):829-843. doi: 10.1080/14712598.2019.1611778. Epub 2019 May 24.
6
Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.利妥昔单抗可有效清除多发性硬化症患者体内增多的表达CD20的T细胞。
J Immunol. 2014 Jul 15;193(2):580-586. doi: 10.4049/jimmunol.1400118. Epub 2014 Jun 13.
7
B cell-directed therapies in multiple sclerosis.多发性硬化症中的B细胞定向疗法。
Neurodegener Dis Manag. 2016;6(1):37-47. doi: 10.2217/nmt.15.67.
8
Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.亚最大量C1q的结合促进了用抗CD20单克隆抗体奥法木单抗（OFA）或利妥昔单抗（RTX）调理的B细胞的补体依赖性细胞毒性（CDC）：与RTX相比，OFA诱导的CDC水平要高得多。
J Immunol. 2009 Jul 1;183(1):749-58. doi: 10.4049/jimmunol.0900632. Epub 2009 Jun 17.
9
Treatment of multiple sclerosis with anti-CD20 antibodies.抗 CD20 抗体治疗多发性硬化症。
Clin Immunol. 2012 Jan;142(1):31-7. doi: 10.1016/j.clim.2011.04.005. Epub 2011 Apr 15.
10
The different clinical effects of anti-BLyS, anti-APRIL and anti-CD20 antibodies point at a critical pathogenic role of γ-herpesvirus infected B cells in the marmoset EAE model.抗 BLyS、抗 APRIL 和抗 CD20 抗体的不同临床效果表明，γ 疱疹病毒感染的 B 细胞在狨猴 EAE 模型中具有关键的致病作用。
J Neuroimmune Pharmacol. 2013 Jun;8(3):727-38. doi: 10.1007/s11481-013-9448-6. Epub 2013 Mar 19.
引用本文的文献
1
Overtime Challenges of Diagnosis and Treatment in Two Pediatric Patients with Extensive Cerebral Tumefactive Lesions Indicative of Baló's Type Multiple Sclerosis.两名患有广泛脑肿瘤样病变提示巴洛型多发性硬化症的儿科患者诊断和治疗的长期挑战
Children (Basel). 2025 May 14;12(5):630. doi: 10.3390/children12050630.
2
Mesenchymal stem cells and their derived exosomes in multiple sclerosis disease: from paper to practice.间充质干细胞及其衍生的外泌体在多发性硬化症中的作用：从理论到实践。
Mol Cell Biochem. 2024 Jul;479(7):1643-1671. doi: 10.1007/s11010-024-05051-8. Epub 2024 Jul 8.
3
Mitochondrial and metabolic dysfunction of peripheral immune cells in multiple sclerosis.多发性硬化症外周免疫细胞的线粒体和代谢功能障碍。
J Neuroinflammation. 2024 Jan 20;21(1):28. doi: 10.1186/s12974-024-03016-8.
4
Repeated iv anti-CD20 treatment in multiple sclerosis: Long-term effects on peripheral immune cell subsets.多发性硬化症中重复静脉注射抗 CD20 治疗：对外周免疫细胞亚群的长期影响。
Ann Clin Transl Neurol. 2024 Feb;11(2):450-465. doi: 10.1002/acn3.51965. Epub 2024 Jan 10.
5
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.抗 CD20 单克隆抗体的主要特征及其对多发性硬化症治疗的临床意义。
J Neurol. 2024 Apr;271(4):1515-1535. doi: 10.1007/s00415-023-12007-3. Epub 2023 Oct 31.
6
Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey.患者和护士对多发性硬化症中 Sensoready 自动注射器笔与其他自动注射器的偏好：来自一项试点多中心调查的结果。
BMC Neurol. 2023 Feb 27;23(1):85. doi: 10.1186/s12883-023-03100-1.
7
From bedside to bench: how existing therapies inform the relationship between Epstein-Barr virus and multiple sclerosis.从床边到实验室：现有疗法如何揭示爱泼斯坦-巴尔病毒与多发性硬化症之间的关系。
Clin Transl Immunology. 2023 Feb 23;12(2):e1437. doi: 10.1002/cti2.1437. eCollection 2023.
8
Immunoregulation via Cell Density and Quorum Sensing-like Mechanisms: An Underexplored Emerging Field with Potential Translational Implications.通过细胞密度和群体感应样机制进行免疫调节：一个具有潜在转化意义的探索不足的新兴领域。
Cells. 2022 Aug 6;11(15):2442. doi: 10.3390/cells11152442.
9
Dissection of multiple sclerosis genetics identifies B and CD4+ T cells as driver cell subsets.多发性硬化症遗传学研究揭示 B 细胞和 CD4+T 细胞是驱动细胞亚群。
Genome Biol. 2022 Jun 7;23(1):127. doi: 10.1186/s13059-022-02694-y.
10
Prioritization of autoimmune disease-associated genetic variants that perturb regulatory element activity in T cells.优先考虑自身免疫性疾病相关的遗传变异，这些变异会干扰 T 细胞中调节元件的活性。
Nat Genet. 2022 May;54(5):603-612. doi: 10.1038/s41588-022-01056-5. Epub 2022 May 5.
本文引用的文献
1
Granulocyte-macrophage colony-stimulating factor as a mediator of autoimmunity in multiple sclerosis.粒细胞-巨噬细胞集落刺激因子在多发性硬化症中的自身免疫作用。
J Neuroimmunol. 2018 Oct 15;323:1-9. doi: 10.1016/j.jneuroim.2018.07.002. Epub 2018 Jul 5.
2
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?克拉屈滨：在资源匮乏地区用于多发性硬化症患者的超说明书疾病修饰治疗？
Mult Scler J Exp Transl Clin. 2018 Jun 26;4(2):2055217318783767. doi: 10.1177/2055217318783767. eCollection 2018 Apr-Jun.
3
Reassessing B cell contributions in multiple sclerosis.重新评估多发性硬化症中的 B 细胞贡献。
Nat Immunol. 2018 Jul;19(7):696-707. doi: 10.1038/s41590-018-0135-x. Epub 2018 Jun 20.
4
Targeting B Cells and Plasma Cells in Autoimmune Diseases.靶向自身免疫性疾病中的 B 细胞和浆细胞。
Front Immunol. 2018 Apr 23;9:835. doi: 10.3389/fimmu.2018.00835. eCollection 2018.
5
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.综合分析揭示 CD38 是富含浆细胞的前期疾病和已确诊的类风湿关节炎及系统性红斑狼疮的治疗靶点。
Arthritis Res Ther. 2018 May 2;20(1):85. doi: 10.1186/s13075-018-1578-z.
6
B Cell Modulation Strategies in Autoimmune Diseases: New Concepts.B 细胞调节策略在自身免疫性疾病中的应用：新概念。
Front Immunol. 2018 Apr 13;9:622. doi: 10.3389/fimmu.2018.00622. eCollection 2018.
7
The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies.B 细胞在多发性硬化症中的多重角色及其在多发性硬化症治疗中的意义。
Cold Spring Harb Perspect Med. 2019 Apr 1;9(4):a029108. doi: 10.1101/cshperspect.a029108.
8
B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.中枢神经系统自身免疫中基于B细胞的疗法：区分CD19和CD20作为治疗靶点。
Ther Adv Neurol Disord. 2018 Mar 21;11:1756286418761697. doi: 10.1177/1756286418761697. eCollection 2018.
9
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.克拉屈滨治疗多发性硬化症与记忆 B 细胞耗竭有关。
J Neurol. 2018 May;265(5):1199-1209. doi: 10.1007/s00415-018-8830-y. Epub 2018 Mar 17.
10
MS drug is suspended after reports of inflammatory brain disorders.在有炎性脑部疾病的报告后，多发性硬化症药物被暂停使用。
BMJ. 2018 Mar 8;360:k1114. doi: 10.1136/bmj.k1114.
Zotero 插件